|Datasheet||Specific References||Reviews||Related Products||Protocols|
|Vector Type||Mammalian Expression Vector|
|Expression Method||Constiutive, Stable / Transient|
|Selection In Mammalian Cells||Hygromycin|
A myc tag can be used in many different assays that require recognition by an antibody. If there is no antibody against the studied protein, adding a myc-tag allows one to follow the protein with an antibody against the Myc epitope. Examples are cellular localization studies by immunofluorescence or detection by Western blotting.
The peptide sequence of the myc-tag is: N-EQKLISEEDL-C (1202 Da). It can be fused to the C-terminus and the N-terminus of a protein. It is advisable not to fuse the tag directly behind the signal peptide of a secretory protein, since it can interfere with translocation into the secretory pathway.
|Mouse IGF-II ORF mammalian expression plasmid, C-GFPSpark tag||MG50040-ACG|
|Mouse IGF-II ORF mammalian expression plasmid, C-OFPSpark / RFP tag||MG50040-ACR|
|Mouse IGF-II ORF mammalian expression plasmid, C-Flag tag||MG50040-CF|
|Mouse IGF-II ORF mammalian expression plasmid, C-His tag||MG50040-CH|
|Mouse IGF-II ORF mammalian expression plasmid, C-Myc tag||MG50040-CM|
|Mouse IGF-II ORF mammalian expression plasmid, C-HA tag||MG50040-CY|
|Mouse IGF-II Gene cDNA clone plasmid||MG50040-M|
|Mouse IGF-II ORF mammalian expression plasmid, N-Flag tag||MG50040-NF|
|Mouse IGF-II ORF mammalian expression plasmid, N-His tag||MG50040-NH|
|Mouse IGF-II ORF mammalian expression plasmid, N-Myc tag||MG50040-NM|
|Mouse IGF-II ORF mammalian expression plasmid, N-HA tag||MG50040-NY|
|Mouse IGF-II natural ORF mammalian expression plasmid||MG50040-UT|
|Learn more about expression Vectors|
Insulin-like growth factor 2 (IGF-2/IGF-II) is a member of the insulin family of polypeptide growth factors, which are involved in development and growth. It is an imprinted gene, expressed only from the paternal allele, and epigenetic changes at this locus are associated with Wilms tumour, Beckwith-Wiedemann syndrome, rhabdomyosarcoma, and Silver-Russell syndrome. IGF-2/IGF-II is a mediator of prolactin-induced alveologenesis; prolactin, IGF-2, and cyclin D1, all of which are overexpressed in breast cancers, are components of a developmental pathway in the mammary gland. IGF-2 and exhibited statistically significant, positive associations with colorectal cancer risk when cases were confined to those diagnosed within a relatively short time period after enrolment. Circulating IGF-2 and IGFBP-3 can serve as early indicators of impending colorectal cancer. IGF-2/IGF-II appears to be involved in the progression of many tumours. It binds to at least two different types of receptor: IGF type 1 (IGF 1R) and mannose 6-phosphate/IGF type 2 (M6-P/IGF 2R). Ligand binding to IGF 1R provokes mitogenic and anti-apoptotic effects. M6-P/IGF 2R has a tumour suppressor function—it mediates IGF 2 degradation. Mutation of M6-P/IGF 2R causes both diminished growth suppression and augmented growth stimulation. The aim of this study was to investigate the role of IGF 2 and its receptors (IGF 1R and IGF 2R) in human gastric cancer.